載入中
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
收盤時
US$9.05
+US$0.0617 · +0.69%
盤後
US$9.17
+US$0.12 · +1.33%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
日內區間
目前US$9.05
52週區間
目前US$9.05
盤中時間採用ET。市場資料可能有所延遲。
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
日內區間
目前US$9.05
52週區間
目前US$9.05
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 34.2萬 USD | 11.8萬 USD | 4000 USD | 5000 USD | 6000 USD |
| 毛利 | −34.2萬 USD | −11.8萬 USD | −4000 USD | −5000 USD | −6000 USD |
| 研究與開發 | 213.3萬 USD | 53.4萬 USD | 33.2萬 USD | 34.7萬 USD | 24.5萬 USD |
| 銷售、一般及管理費用 | 377.4萬 USD | 76.8萬 USD | 30.3萬 USD | 54.8萬 USD | 45.2萬 USD |
| 營業費用 | 590.7萬 USD | 130.2萬 USD | 63.5萬 USD | 89.5萬 USD | 69.7萬 USD |
| 利息收入 | 37萬 USD | — | — | — | — |
| 利息支出 | 314.3萬 USD | 3000 USD | 2000 USD | 2000 USD | 2000 USD |
| 折舊和攤銷 | 34.2萬 USD | 11.8萬 USD | 4000 USD | 5000 USD | 6000 USD |
| 營業利益 | −624.9萬 USD | −130.2萬 USD | −63.5萬 USD | −89.5萬 USD | −70.3萬 USD |
| 淨利 | −333.5萬 USD | −154.5萬 USD | −60萬 USD | −77.9萬 USD | −71.1萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年11月28日 | 1:6 | — | — |
股票分割 | 2025年5月27日 | 1:250 | — | — |
已生效 2025年11月28日
1:6
已生效 2025年5月27日
1:250
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
